Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature (Q38114629)

29 August 2017

title

Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature (English)

1 reference

29 August 2017

1 reference

1 reference

Tsutomu Nishiyama

1

1 reference

29 August 2017

language of work or name

1 reference

13 June 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

32

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

38.e17-28

1 reference

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Incomplete Testosterone Suppression in Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Abiraterone and increased survival in metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Increased survival with enzalutamide in prostate cancer after chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Cell biology of Leydig cells in the testis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Biological Actions of Androgens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Testosterone, Bone and Osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Leydig cell aging and the mechanisms of reduced testosterone synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

At the crossroads of steroid hormone biosynthesis: the role, substrate specificity and evolutionary development of CYP17.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Cytochrome b(5) modulation of 17{alpha} hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Regulation of the adrenal androgen biosynthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Serum prostate‐specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Adrenocorticotropic Hormone is Involved in Regulation of Androgen Synthesis in Men Receiving Androgen Deprivation Therapy for Localized Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Effect of castration monotherapy on the levels of adrenal androgens in cancerous prostatic tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Luteinizing Hormone (LH)–Releasing Hormone Agonist Reduces Serum Adrenal Androgen Levels in Prostate Cancer Patients: Implications for the Effect of LH on the Adrenal Glands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Lower Testosterone Levels With Luteinizing Hormone-Releasing Hormone Agonist Therapy Than With Surgical Castration: New Insights Attained by Mass Spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Secondary hormonal therapy for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

The androgen axis in recurrent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Serum Testosterone Level to Predict the Efficacy of Sequential Use of Antiandrogens as Second-line Treatment Following Androgen Deprivation Monotherapy in Patients with Castration-resistant Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Investigation into possible causes of interference in serum testosterone measurement in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Preface. CDC workshop report improving steroid hormone measurements in patient care and research translation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Toward Excellence in Testosterone Testing: A Consensus Statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

DETERMINATION OF TESTOSTERONE IN HUMAN PERIPHERAL AND ADRENAL VENOUS PLASMA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

GnRH agonists, antagonists, and assisted conception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Testosterone surge: rationale for gonadotropin-releasing hormone blockers?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

3-Month Formulation of Goserelin Acetate (‘Zoladex’ 10.8-mg Depot) in Advanced Prostate Cancer: Results from an Italian, Open, Multicenter Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Goserelin versus leuprolide in the chemical castration of patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Surgical castration in hormone-refractory metastatic prostate cancer patients can be an alternative for medical castration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

Gonadotropin‐releasing hormone: An update review of the antagonists versus agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

The Efficacy and Safety of Degarelix, a GnRH Antagonist: A 12-month, Multicentre, Randomized, Maintenance Dose-finding Phase II Study in Japanese Patients with Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone‐releasing hormone agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.03.007

10.1016/J.UROLONC.2013.03.007

7 January 2021

Identifiers

DOI

1 reference

29 August 2017

1 reference